Literature DB >> 6195613

The use of amiodarone in children.

P Coumel, V Lucet, D Do Ngoc.   

Abstract

Our use of amiodarone in 200 patients during an 8-year period confirms our previous experience which indicated that the drug was close to being the ideal antiarrhythmic agent in children's arrhythmias. Its absence of cardiac toxicity, its powerful antiarrhythmic properties, its depressive effect on the AV nodal conduction, combined with its beta-inhibitory effect makes it effective and harmless in practically all forms of atrial, junctional and ventricular arrhythmias, whatever the reentrant or automatic mechanism of the arrhythmia. The metabolism is much faster in children than in adults, making the drug active in a few hours, with a lesser prolonged duration of action. Though there is practically no limitation for its use on a short- or mean-term basis, the long-term use must be limited to truly refractory arrhythmias, a situation which is rarely encountered. In such cases, combining amiodarone with conventional therapy allows a decrease in the maintenance dosage and a lower incidence of extracardiac side effects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6195613     DOI: 10.1111/j.1540-8159.1983.tb04415.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  3 in total

1.  Safety of antiarrhythmic drugs in children.

Authors:  J M McComb
Journal:  Br Heart J       Date:  1993-07

2.  Repetitive paroxysms of supraventricular tachyarrhythmias triggered during pediatric cardiac interventions: suppression after short infusion of amiodarone.

Authors:  U Mazić; P Berden; T Podnar
Journal:  Pediatr Cardiol       Date:  2004 Nov-Dec       Impact factor: 1.655

3.  Amiodarone monitoring practices in pediatric hospitals in the United States.

Authors:  Brady S Moffett; Santiago O Valdes; Jeffrey J Kim
Journal:  Pediatr Cardiol       Date:  2013-05-03       Impact factor: 1.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.